Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2507

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2507
---
 exclusive sublicense from Elkurt under Elkurt’s exclusive
    license from Brown University. Specifically, this Elkurt license includes one issued U.S. methods and compositions utility patent
    and three pending utility patent application including applications in the United States, Canada, and Europe. 

    ●
    With
    respect to ODA-570, our Ocean Sihoma, Inc. subsidiary obtained an exclusive sublicense from Elkurt under Elkurt’s exclusive
    license from Rhode Island Hospital. Specifically, this Elkurt license includes eight issued patents including four U.S. patents,
    one European patent validated in seven countries, one South African patent, one African Regional Intellectual Property Organization,
    or ARIPO, patent; one Indian patent; and six pending utility patent applications including applications in the United States, Brazil,
    Europe, India, AIRPO, and Thailand. The issued patents have expected expiration dates in 2032, without accounting for any available
    patent term adjustments or extensions. 

    ●
    With
    respect to ODA-611 and ODA-579, our Ocean Sihoma, Inc. subsidiary also obtained an exclusive sublicense from Elkurt under Elkurt’s
    exclusive license from Rhode Island Hospital. Specifically, this Elkurt license includes eight pending utility patent applications
    in the United States, Canada, Brazil, Europe, South Africa, India, Thailand, and ARIPO. 

Licensing
Agreements

Exclusive
License Agreement with Elkurt for (FRG) Antibody

On
July 31, 2020, we entered into an exclusive license agreement, or the FRG License Agreement, with Elkurt, Inc., or Elkurt, for OCX-253.
We further sub-licensed this program to our Ocean Chitorx, Inc. subsidiary on February 25, 2021. We amended the FRG License Agreement
on March 21, 2021, August 31, 2021, March 25, 2022, July 1, 2022, July 2, 2022, August 25, 2022, November 1, 2023 and June 13, 2024.
Pursuant to the FRG License Agreement, we obtained from Elkurt an exclusive, royalty-bearing license under certain patent rights, or
the FRG Patents, and a nonexclusive, royalty-bearing license under certain data, expression and purification methods, information and
other know-how, or the FRG Know-